36 results about "Cancer surgery" patented technology

The invention provides a medicine for remedying cancer, in particular to a medicine for remedying various cancers after surgery. The medicine is characterized in that No. I recipe takes radix rehmanniae, red peony root, bletilla, Szechwan lovage rhizome, wine-madder, salvia, panpax notoginseng, dandelion, APN, rhodiola himalensis, raw radix astragali, angelica, wolfberry fruit, chinese yam, radix pseudostell, membrane of chicken gizzard, asparagus, trichosanthin, hawthorn and so on as raw materials; No. II recipe takes vinegar leaching and frying turtle shell, dried lacquer, duchesnea indica, citrus aurantium, earth frying atractylodes, areca nut, mythic fungus, dodder, sang, raw ochre, pubescent holly, honeysuckleand so on as raw materials; No. III recipe takes sang, liriope, liquorices, cinnamon, herba cistanches, wolfberry fruit and so on as raw materials. The recipes are separately made into decoction in proportion. The medicine uses the comprehensive effect of each medicine to remedy various cancers that have been processed with surgery. The medicine can remove blood heat, influence blood, active blood without randomly influencing, stop blood, eliminate blood stasis, produce new blood and drain deteriorated blood without harm to new blood. The clinical treatment shows that the medicine has significant efficacy.

The present invention relates generally to the field of fluorescent dyes as a system useful for surgery imaging. More particularly, the present invention relates to systems, methods and kits for exciting fluorescent, phosphorescent or luminescent molecules with light from a light source and detecting the relative fluorescent, phosphorescent, or luminescent light intensity emitted from the fluorescent, phosphorescent, or luminescent molecule. Such systems may be applied as mapping agents for various surgical techniques, such as for cancer surgeries and biopsies.

The present invention relates to a novel system for predicting a prognosis capable of predicting the prognosis of locally advanced gastric cancer, and more specifically, capable of predicting a clinical result after a resection during gastric cancer surgery through gene set enrichment comparative analysis.

Provided is a device capable of determining whether or not cancer has metastasized to a sentinel lymph node, such as the axillary lymph node, thickly covered with fat, safely and in a simple manner without confirmation by biopsy or extirpation. Fluorescence generated in a sentinel lymph node upon the excitation of protoporphyrin (a photosensitizing substance) derived from 5-ALA administered to a subject can be detected by passing a hollow tube, into which a small-diameter optical fiber for launching light and the small-diameter optical fiber for receiving light are inserted, through the lymph vessel to identify the presence or absence of the metastasis of cancer cells even before the surgery of cancer or during prognosis.

The invention provides a device for cancer surgery fluorescence guiding and residual cancer tracing and clearing. The device is formed by combination of a host, an image lighting and acquiring unit and a photodynamics therapy irradiator, wherein the host is provided with a program controller, a fluorescence-reflected light image processor, an image displayer and an image lighting and therapy lighting source. Surgical navigation can be conducted after a proper amount of target nanometer photosensitizer is injected into the body of a patient, residual cancer tracing is conducted in surgery, and key information is provided for precise treatment of cancer patients. Peripheral occult cancer and residual cancer in blood can be detected, tumor cells are killed selectively, photodynamics therapy which hardly causes damage to healthy tissue is adopted, and residual cancer is eradicated. In this way, radiotherapy and chemotherapy quite harmful to health do not need to be adopted to prevent canceration, recurrence and metastasis after cancer surgery treatment, the survival rate of cancer patients can be increased greatly, and the living quality of cancer patients in the recovery period can be improved greatly.

The present invention relates to a cancer operating room failure rate analysis device, comprising: a high-angle photographing device including a mobile cradle head capable of being disposed on the topof a cancer operating room to perform photographing operation on the internal environment of the cancer operating room to obtain and output a corresponding internal image of the cancer operating room; a fault notification device, used for receiving the fault rate, sending out an overall replacement instruction when the fault rate exceeds a preset percentage threshold value, and sending out a usemaintaining instruction when the fault rate does not exceed the preset percentage threshold value; a fault notification device, comprising an LED display screen arranged on the mobile holder and a voice playing chip arranged on the mobile holder. The failure rate analysis device for the cancer operating room is simple to operate and convenient for reference. As the visual analysis mode is adoptedto effectively detect the failure rate, the original rough manual detection mode is replaced, and the detection speed and precision are improved.

The present invention discloses a ginger pop taro bean curd, which is prepared from the following raw materials by weight: 100-110 parts of soybean, 20-30 parts of taro, 0.8-1 part of hypericum japonicum thunb, 1-1.2 parts of kirilow rhodiola root and rhizome, 0.8-1 part of curcuma, 1-2 parts of lotus pedicle (b), 3-4 parts of crab meat (/b), 3-4 parts of blood glutinous, 2-3 parts of undaria pinnitafida, 1-1.1 parts of purple cabbage, 0.9-1.1 parts of robiniae, 3-4 parts of bananas, 2-3 parts of fresh ginger, 2-3 parts of gynura divaricata, 1-2 parts of corn oil, 4-5 parts of red bean flour, 4-5 parts of duck meat, 1-2 parts of brine and 4-5 parts of nutritional additives. The bean curd in the present invention has strong fragrance. The added taro contains a plurality of trace elements that can enhance the body's immune function. The bean curd can be used as staple food of regular medicated diet for prevention and treatment of cancer, has good assistant effect for the rehabilitation process after cancer surgery or postoperative radiotherapy and chemotherapy, and has functions of teeth cleaning, dental caries preventing and teeth protecting. In addition, in the production process of the present invention, a plurality of Chinese herbs are added to provide efficacy of strengthening spleen and stomach, regulating middle energizer qi, dispelling wind-evil, activating blood circulation, removing summer-heat and eliminating dampness.

The present invention is concerned with an in vitro method of diagnosing cancer in a tissue sample, wherein said tissue sample is obtained from a patient undergoing cancer surgery. The method described herein is based on a hyperpolarized marker, which is contacted with the tissue sample, and an NMR spectrum and/or an MR image obtained of the tissue sample after having been contacted with the hyperpolarized marker.

The inventors found that postsurgical recurrence and/or metastasis of cancer is suppressed by administering a beta-blocker to a cancer patient during a perioperative period of cancer surgery. Accordingly, the disclosure provides an agent for suppressing recurrence and/or metastasis of cancer, comprising a beta-blocker and being administered during a perioperative period of cancer surgery.

A targeted drug delivery device comprises a brush for use in delivery of one or more therapeutic agents during surgical procedures, including but not limited to, heart, chest, abdominal, brain, limb, vascular, eye, organ transplantation surgery or cancer surgical treatment. The therapeutic agent is selected from the group consisting of genetically engineered vectors or cells, proteins, stem cells, small molecule pharmaceuticals, drugs or biologics. Methods of treating diseases comprising delivering at least one therapeutic agent to a patient's organs or tissues using any one of the targeted drug delivery devices are disclosed.